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Abstract
To determine the prevalence of substandard drugs in urban (Ulaanbaatar) and rural (selected provinces) areas of
Mongolia, samples of 9 common, therapeutically important drugs were collected from randomly selected drug
outlets in Ulaanbaatar and 4 rural provinces by “mystery shoppers”. Samples were analyzed by visual inspection,
registration status, and biochemical analysis. Samples failing to meet all Pharmacopeia quality tests were considered
substandard.
In the rural provinces, 69 out of 388 samples were substandard, giving an estimated prevalence of substandard drugs
of 17.8% (95% CI: 14.1-22.0). There were 85 unregistered samples, giving a prevalence estimate of unregistered drugs of
21.9%. (95% CI: 17.9-26.3). In the urban Ulaanbaatar districts, 112 out of 848 samples were substandard, giving an
estimated prevalence of substandard drugs of 13.2% (95% CI: 11.0-15.7). There were 150 unregistered samples, giving a
prevalence estimate of unregistered drugs of 17.7% (95% CI: 15.2-20.4).
In the rural provinces, 35 out of 85 (41.2%) unregistered samples were substandard; whereas 34 out of 303 (11.2%)
registered samples were substandard. (p<0.0001) In the urban districts, 18 out of 150 (12.0%) unregistered samples
were substandard, whereas 94 out of 698 registered were substandard. (13.5%) (p=0.6).
The prevalence of substandard and unregistered drugs is higher in rural provinces. There is a significant association
between substandard and unregistered drugs in the provinces but not in the urban districts. The underlying causes for
substandard drugs need to be further investigated in order to help formulate strategies to improve pharmacovigilance
and the drug supply quality in Mongolia.
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Background
Poor quality drugs have been increasingly recognized as a
global public health threat because they have the potential
to result in inadequate treatment, cause adverse effects
from toxic ingredients, and promote drug resistance. The
nomenclature of the categories of poor quality medications
can be confusing. The World Health Organization recently
chose to group all categories together as “SSFFC”:s u b -
standard, spurious, falsely-labeled, falsified, and counterfeit.
Revision of these categories as: “substandard” -d r u g st h a t
for unintentional reasons do not meet the legally required
quality specifications of a country’s regulators, “unregis-
tered” - drugs that do not have the legally required market-
ing authorization from the country’s regulators, and
“falsified” - drugs that are unlawful, and violate the regula-
tors quality specifications, with criminal intent was subse-
quently suggested (Attaran et al. 2012). Fernandez, et al.
raise the issue that a genuine drug found to have an insuffi-
cient amount of an active ingredient could be substandard
or degraded (Fernandez et al. 2011), indicating poor quality
drugs can result from issues in production or external fac-
tors such as environmental conditions, impacting quality
after distribution.
The true extent of the problem is difficult to ascertain.
Reasons for this include the difficulty and expense in
performing a methodologically sound study, reluctance
of governments to disclose information and the fact that
many of the effects on patients are difficult to detect and
hidden in other public health statistics (Cockburn et al.
2005). In his 2010 article, Newton states there is an ur-
gent need for data of sufficient sample size, with random
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quality medicines (Newton, et al. 2010) Literature reviews
of prevalence studies on falsified/substandard drugs report
that the percentage of substandard drugs in various Asian
and African countries range from 8-46% (Caudron et al.
2008), and the median prevalence of substandard/falsified
medicines was 28.5% (range 11–48%) (Almuzaini et al.
2013). The World Health Organization (WHO) conducted
a survey on the quality of selected anti-malarial medication
in 6 subSaharan African countries, which found that 28.5%
of the samples failed to meet testing requirements, with
11.6% having extreme deviations, and therefore likely to
have negative health implications (Sabartova et al. 2011a).
Another WHO survey was conducted on the quality of
anti-tuberculosis medications in Russia, and found 11.3% of
the samples failed to meet study specifications, with 1.0%
having extreme deviations (Sabartova et al. 2011b). In 1999,
WHO conducted a survey of drug quality in Myanmar and
Vietnam, and found that 16% of the samples did not meet
all specifications of testing (Wondemagegnehu 1999).
Between 2004–2006 the pharmaceutical procurement
system in Mongolia underwent decentralization, and is
now 100% privatized. In the current system, the Division
of Pharmaceutical and Medical Devices, Mongolian
Ministry of Health (MoH) is responsible for the policy,
planning and regulatory affairs in providing pharmaceut-
ical care in Mongolia. The special licenses for manufac-
turing, importing, purchasing pharmaceuticals and
medical devices are granted by the Special Permission
Committee of the MoH. Drugs are distributed through
drug wholesalers and retail drug outlets (community
pharmacies and revolving drug funds (RDF)). Whole-
salers can import and procure drugs with an approval
and special permission from the Mongolian Minister of
Health. In 2011, there were 158 registered drug whole-
saling companies and 42 local drug manufacturing
companies, some of which act as both wholesalers and re-
tailers. Approximately 85% of all drugs are imported from
other countries, primarily Russia and India, followed by
Germany, Slovenia and China.
Poor quality drugs have been a concern in Mongolia,
supported by the findings from a 2006 study on unregis-
tered, falsified and substandard drugs (Mongolia Ministry
of Health 2006). Using convenience sampling methods,
225 samples were collected from 40 drug outlets around
the country, 55 of which were felt to be “suspicious” and
were sent for further testing. Sixteen of these were felt to
be “inconsistent” and 8 were possibly counterfeit. A 2008
study by Tsetsegmaa found that 11 of the 16 medications
reported in the surveillance were substandard (Tsetsegmaa
2008). In a 2009 report, lack of knowledge about the ef-
fectiveness of drug quality monitoring in Mongolia was re-
ported as a gap that should be a priority for further
investigation (Abdelkrim 2009).
This research study was undertaken to address these
concerns, and provide data of good methodological qual-
ity to accurately determine the prevalence of substand-
ard drugs in the rural and urban areas of Mongolia after
the decentralization and privatization of the Mongolian
pharmaceutical system. This information will be of value
to Mongolian policy makers, public health officials and
pharmaceutical practitioners to reliably determine the
extent of the problem, and then can serve as a valid
comparison for future studies to evaluate interventions
to improve the drug supply quality. It will also help
guide further research to better understand the health
impact of poor quality medications in Mongolia.
Methods
Site selection
Mongolia is a landlocked country in north central Asia,
with 21 rural provinces, plus 1 municipality, the capital
city of Ulaanbaatar where over 60% of the population lives.
Because the conditions in rural provinces vary greatly
from the urban area of Ulaanbaatar, samples were col-
lected, analyzed, and reported independently. Samples for
this study were collected from 4 districts in Ulaanbaatar
(Chingeltei, Khan-Uul, Bayanzurkh, and Songinokhair)
and 4 rural provinces (Bayan-Uglii, Dornogobi, Selenge,
and Umnugobi) representing the main geographic regions
of the country. Samples were obtained from the different
types of drug outlets in the provinces: Revolving Drug
Fund (RDF- a government outlet), retail pharmacy outlets,
and wholesalers. In Ulaanbaatar districts, samples were
only obtained from retail pharmacy outlets and whole-
salers, as RDF outlets are only present in the provinces.
Samples from unofficial drug outlets and the informal
market were not included in this study.
Medications included in the study were selected based
on high therapeutic importance and utilization based on
discussions with local experts from Schools of Pharmacy,
Public Health, and Mongolian National University of
Medical Sciences. They are all on the Essential Drug List
and available with or without a prescription. All samples
were tablets or capsules and include antimicrobials (ampi-
cillin, amoxicillin, co-trimoxazole, metronidazole, doxy-
cycline, nystatin), analgesics (paracetamol and ibuprofen),
and bromhexin, a commonly used medication for respira-
tory illness (Table 1).
Sample size calculation
Prevalence studies from other countries indicate a wide
range of substandard drugs, 8-46% (Caudron et al. 2008),
and 11–48% (Almuzaini et al. 2013). Based on this infor-
mation and the previous studies of falsified/substandard
drugs in Mongolia, we targeted our sample size to detect
at least a 5% prevalence (alpha of 0.05 and beta of 0.9).
This calculation was 134 samples for each drug (1206 for
Khurelbat et al. SpringerPlus 2014, 3:709 Page 2 of 10
http://www.springerplus.com/content/3/1/709all drug types combined) distributed among the provinces
or districts. In order to detect a 10% prevalence, the sam-
ple size needed was 67 (603 combined) and 15% preva-
lence was 38 samples (342 combined).
Sampling techniques
The sampling strategy included weighting the sample
size by population and the number of the types of drug
outlets in the province or district. Drug outlets to be
sampled were selected randomly.
A sample was defined as 100 dosage units (tablet or
capsule) of a given drug of the same lot number pur-
chased in blister packs of 10 dosage units.
Samples were collected from the 4 provinces between
May 2012 and September 2012 and from the 4 Ulaanbaatar
districts between July 2012 and March 2013 by “mystery
shoppers”. These were trained field workers, who presented
themselves as local customers, and followed the study
protocol for obtaining drug samples based on recom-
mended sampling techniques (Newton et al. 2009). If they
were unable to purchase the necessary quantity for a
complete sample from one batch or lot, this was noted and
attempts were made to purchase it from another randomly
selected outlet of the same type. Collected samples were
placed in a box, then transported to and stored in lockers
at the School of Pharmacy, Mongolian National University
of Medical Sciences. The transport box and lockers met the
temperature and humidity requires of the WHO Guidelines
for the Sampling of Pharmaceutical Products, and were ac-
c e s s i b l eo n l yb yt h em a i ns t u d yi n v e s t i g a t o r .
Sample analysis
Sample analysis for each sample consisted of visual inspec-
tion of the packaging and labeling, and determination of
registration status, expiration date, country of manufac-
ture, biochemical analysis, and company of manufacture.
An online database developed by the Ministry of Health in
Mongolia (Licemed) and archive documents from the
registration of drugs were used to complete the visual in-
spection. The database includes information such as size,
color, labeling and numbers of the packages and labeling.
In addition, the WHO guideline for the Development of
Measures to Combat Counterfeit Drugs was used. (World
Health Organization 1999) A sample was considered sus-
picious if the package and labeling was not consistent with
registered information for that drug and manufacturer.
Samples with suspicious packaging and labeling were sent
to the manufacturers for confirmation. If the manufacturer
confirmed that it was their product, the sample was con-
sidered acceptable.
The registration status of all samples was determined by
visual inspection of the packaging, and then confirmed
using the drug registration archives at the Mongolian
Ministry of Health. Registration was not considered a re-
quirement for determining whether or not a sample was
substandard.
Drug samples underwent biochemical analysis by 1 of
3 laboratories in Mongolia: Drug and Bio-preparation
Central Laboratory of Specialized Professional Inspec-
tion Agency (SPIA); Drug Control Laboratory, School of
Pharmacy, Mongolian National University of Medical Sci-
ences; and the Drug Testing Laboratory “Monos Group”.
These laboratories are accredited by the Standardization
and Technical Regulatory Office of the Centre for
Standardization and Measurement in Mongolia, which is
responsible for the technical standards in local production
and quality control. The Pharmacopoeias were chosen ac-
cording the country of origin of the sample or specification
requirements of the manufacturer (Table 1). (British
Table 1 Drugs in study population
Name of drug Dosage form Pharmacopeia
reference
Metronidazole 250 mg/tab Mongolian National
Pharmacopeia 2011
Pharmacopeia of the
People’s Republic
of China 2005. Vol. II,
Nystatin 500000 ID/tab British Pharmacopeia
2001. Vol.2
Ibuprofen 400 mg/tab Mongolian National
Pharmacopeia 2011
Pharmacopeia of the
People’s Republic
of China 2005. Vol. II,
Co-trimoxazole 480 mg/tab Mongolian National
Standard-MNS
6149-2010
Amoxicillin 500 mg/cap Mongolian National
Pharmacopeia 2011
Paracetamol 500 mg/tab Mongolian National
Pharmacopeia 2011
Pharmacopeia of the
People’s Republic
of China 2005. Vol. II,
Ampicillin 500 mg/cap British Pharmacopeia
2001. Vol. 2
Mongolian National
Pharmacopeia 2011
USP 23
Bromhexin 8 mg/tab Mongolian National
Pharmacopeia 2011
Pharmacopeia of the
People’s Republic of
China 2005. Vol. II,
Doxycycline 100 mg/cap Mongolian National
Standard-MNS
5776–2007
Pharmacopeia of the
People’s Republic
of China 2005. Vol. II,
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Pharmacopeia of the People’s Republic of China 2005).
These requirements vary by drug, and include 8–11 of
the following tests: appearance, assay, disintegration, dis-
solution, hardness, identification, irradiance absorption,
water, friability, weight average and weight variation
(Table 2). The qualitative analysis included: 1). visual in-
spection of package and labeling, 2). characteristics of the
sample (appearance, odor, color dosage form), 3). uniform-
ity of weight, disintegration, and dissolution, 4). identifica-
tion of components by chemical reaction, and thin layer
chromatography, spectrum analysis on UV spectropho-
tometer and IR spectrophotometer. Quantitative analysis
included assay of active compounds by spectrophotomet-
ric, titrometric and chromatographic methods. A sample
was considered to be substandard if it failed to pass all re-
quired tests for the drug required by the article require-
ments in the Pharmacopeia used, that is, if the sample
failed one or more of the required tests it was considered
substandard.
Ethics approval
Ethics approval was obtained from the World Health
Organization Ethics Review Committee and the Medical
Ethics Committee of the Ministry of Health, Mongolia.
Statistical analyses
Measurements were presented as numbers and per-
centages with 95% confidence intervals (CIs), and were
compared with the chi-square test or Fisher’s exact test. P
values <0.05 were regarded as statistically significant.
Results
Description of sample and analysis results
Sample description
The number of samples collected for this study was 388
from the rural provinces and 848 from the urban districts
of Ulaanbaatar. The distribution of the samples based on
location by drug outlet type is presented in Table 3, and
location by drug in Table 4.
Sample inspection
Out of 388 samples from the rural provinces, only 3 were
found to be past expiration date. There were 4 others that
expired within the data collection period of May to August
2012, so may have recently expired. Out of 848 samples
from the Ulaanbaatar districts, none were found to be past
expiration date.
On initial inspection, 22 drug samples from the rural
provinces and urban districts combined were found to
have variation in the packaging and labeling of the drugs
when compared with the products registered in Mongolia.
Upon review by the manufacturer, all 22 were found to be
acceptable or meeting standards due to packaging updates.
Biochemical sample analysis
Failure to pass the assay test (e.g. amount of required ingre-
dients fell outside range of Pharmacopeia standards) was
the most common reason that a sample was found to be
substandard. Failure to pass this test indicates that the sam-
ple did not meet the threshold requirements regarding
amount of drug present and does not give any information
about the degree or direction of deviation from the re-
quired standard (Table 5). In the provincial group, 51 out of
388 (13.4%, 95% CI: 9.9-16.9) samples failed the assay test.
The other common reasons were weight variation and Table 2 Sample analysis definitions
Test Definition
Appearance Clean, smooth surface and uniform color of tablet or
capsule
Friction and
substantial
Tablet crushing strength
Weight average Average weight of 20 tablets
Weight
variation
Difference between the weight of the content of each
solid form and the average weight of solid forms
Disintegration Disintegration or disbursement of solid preparations
into fragments or particles in a liquid medium
Dissolution Rate and degree of dissolution of active ingredients
in liquid medium
Content
uniformity
Contents of single ingredient solid preparations
Water
(Loss on drying)
Determine water loss on drying
Identification Verify identity by visual inspection
Irradiance
absorption
Absorbance in the ultraviolet region
Assay Determine content of active ingredients
Table 3 Number of samples by location and drug outlet
type
Wholesale Retail RDF* Total
N%N%N%N%
Rural provinces
Bayan-Ulgii 15 3.9 77 19.8 34 8.8 126 32.5
Dornogobi 14 3.6 30 7.7 36 9.3 80 20.6
Selenge 12 3.1 52 13.4 58 14.9 122 31.4
Umnugobi 10 2.6 27 7.0 23 5.9 60 15.5
All provinces 51 13.1 186 47.9 151 38.9 388 100
Urban districts
Bayanzurkh 41 4.8 248 29.2 NA NA 289 34.1
Chingeltei 50 5.9 111 13.1 NA NA 161 19.0
Khan-Uul 32 3.8 97 11.4 NA NA 129 15.2
Songinokhairkhan 26 3.1 243 28.7 NA NA 269 31.7
All districts 149 17.6 699 82.4 NA NA 848 100
*RDF: Revolving Drug Fund (government outlet).
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Amoxicillin Ampicillin Bromhexin Co-trimoxazole Doxycycline Ibuprofen Metronidazole Nystatin Paracetamol Total
Rural province N % N % N % N % N % N % N % N % N % N %
Bayan-Ulgii 17 4.4 14 3.6 13 3.4 17 4.4 10 2.6 13 3.4 14 3.6 15 3.9 13 3.4 126 32.5
Dornogobi 11 2.8 8 2.1 8 2.1 10 2.6 10 2.6 8 2.1 8 2.1 9 2.3 8 2.1 80 20.6
Selenge 12 3.1 13 3.4 14 3.6 14 3.6 14 3.6 13 3.4 13 3.4 18 4.6 11 2.8 122 31.4
Umnugobi 6 1.5 5 1.3 6 1.5 6 1.5 9 2.3 9 2.3 6 1.5 7 1.8 6 1.5 60 15.5
All provinces 46 12 40 10 41 11 47 12 43 11 43 11 41 11 49 13 38 10 388 100
Urban district
Bayanzurkh 33 3.9 37 4.4 41 4.8 30 3.5 27 3.2 31 3.7 37 4.4 31 3.7 22 2.6 289 34.1
Chingeltei 24 2.8 15 1.8 13 1.5 18 2.1 17 2.0 20 2.4 21 2.5 19 2.2 14 1.7 161 19.0
Khan-Uul 14 1.7 15 1.8 19 2.2 14 1.7 11 1.3 12 1.4 16 1.9 16 1.9 12 1.4 129 15.2
Songinokhairkhan 30 3.5 27 3.2 33 3.9 33 3.9 28 3.3 32 3.8 35 4.1 34 4.0 17 2 269 31.7
All districts 101 11.9 94 11.1 106 12.5 95 11.2 83 9.8 95 11.2 109 12.9 100 11.8 65 7.7 848 100
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9weight average. There were a few samples failing tests for
dissolution, disintegration and friction (Table 6). In the
Ulaanbaatar district samples, 55 out of 848 (6.6%, 95% CI:
4.9- 8.4 failed the assay test (Table 5). The other common
reasons were disintegration and dissolution. There were a
few samples that failed the following tests weight variation,
weight average, and friction (Table 7).
Prevalence of substandard drugs
Rural provinces
Out of 388 samples collected from all 4 rural provinces,
69 were classified as substandard. This gives a substandard
drug prevalence rate of 17.8% (95% CI: 14.1-22.0) in the
rural provinces (Table 8).
Urban districts
Out of 848 samples collected from all 4 urban districts of
Ulaanbaatar, 112 were classified as substandard. This gives
a prevalence rate of 13.2% (95% CI: 11.0-15.7) substandard
drugs in the urban districts of Ulaanbaatar (Table 8).
Registration status
Rural provinces
Out of 388 samples collected from the 4 provinces, 85
were unregistered. This gives a prevalence estimate of un-
registered drugs in the provinces of 21.9%. (95% CI: 18.0-
26.3) (Table 9). Out of the 85 unregistered samples, 35
were substandard (41.2%), compared with 34 substandard
samples out of the 303 registered samples (11.2%). This is
a statistically significant difference (p <0.0001) (Table 10).
Districts of Ulaanbaatar
Out of 848 samples, collected from the 4 districts of
Ulaanbaatar, 150 were unregistered. This gives a preva-
lence estimate of unregistered drugs in the Ulaanbaatar
districts of 17.7% (95% CI: 15.2-20.4) (Table 9). Out of 150
unregistered samples, 18 were substandard (12.0%), com-
pared with 94 substandard samples out of the 698 regis-
tered samples (13.5%). This difference is not statistically
significant (p=0.6) (Table 10).
Discussion
Our results provide prevalence estimates for substandard
drugs in Mongolia of 17.8% in the rural provinces and
13.2% in the urban districts of Ulaanbaatar, based on
failure to meet the threshold quality standards estab-
lished in the selected Pharmacopeia. While our study de-
sign does not allow us to directly compare these results
from these 2 regions, it is interesting to note a modestly
higher prevalence of substandard drugs in the rural sam-
ple. We also noted a significant association between sub-
standard and unregistered drugs in the provinces, but
not in the urban districts.
Our prevalence estimates of substandard drugs of
17.8% and 13.2% in Mongolia are in alignment with the
range of 11-14% reported by Almuzaini et al. in their re-
cent review of substandard and falsified medications in
low and middle income countries in Asia and Africa
(Almuzaini et al. 2013). Our prevalence estimates are
lower than the median percentage of 28% reported in
this review, however, this comparison is limited by the
differences in methodology, sample size, inclusion cri-
teria and drugs selected between the various studies re-
ported and ours. The most common reason for a sample
to be substandard was failure to pass assay test, which is
consistent with the findings of other studies (Almuzaini
et al. 2013). Failure to pass the assay test, along with fail-
ure to pass the disintegration and dissolution tests, the
other most common reasons in our study, indicates that
the bioavailability of the active ingredients was compro-
mised. This can lead to ineffective treatment, and in the
case of antibiotics, promote drug resistance. Of note,
almost none of the samples were found to be post-
expiration date, suggesting other factors are contributing
to the degradation in drug quality. Further investigation
into drug transport and storage conditions may help bet-
ter understand this, especially given the extreme weather
conditions found in Mongolia.
Another interesting finding of our study was the 21.9%
prevalence of unregistered drugs in the provinces and
17.7% in the districts of Ulaanbaatar. This raises the im-
portance of further investigation of the drug supply
chain and evaluation of drug regulatory policies. Such
initiatives could be undertaken at the national level and
through collaborations with neighboring countries. We
believe this may be an especially important step to im-
prove the quality of the drug supply in the provinces
where there was a statistically significant association be-
tween unregistered and substandard drug samples.
An adequate sample size is essential to obtaining valid
results. Our sample size calculations indicated that we
would need 342 samples for each region to detect a 15%
prevalence. We achieved this in both the rural provinces
(N =388, 17.8% prevalence) and the urban districts (N=
848, 13.2% prevalence). However, there are some weak-
nesses in our study that could underestimate our preva-
lence estimates. These include the potential for drug
outlet personnel to selectively provide drugs if they were
suspicious about the reason for the purchase, and
Table 5 Number of samples failing assay by location
Rural Urban
N % 95% CI* N % 95% CI*
Failed assay 51 13.1 9.9, 16.9 55 6.5 4.9, 8.4
Passed assay 337 86.9 83.1, 90.1 793 93.5 91.6, 95.1
Total 388 100 848 100
*CI: confidence interval
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Amoxicillin Ampicillin Bromhexin Co-trimoxazole Doxycycline Ibuprofen Metronidazole Nystatin Paracetamol Total
#%#%#% # % # %#% # % #%# % # %
Not acceptable
Assay 2 1% 0 0% 0 0% 6 2% 4 1% 11 4% 17 6% 7 3% 4 2% 51 2%
Disintegration 0 0% 0 0% 0 0% 1 0% 0 0% 5 2% 1 0% 0 0% 0 0% 7 0%
Dissolution 1 0% 0 0% 0 0% 0 0% 0 0% 5 2% 2 1% 0 0% 3 1% 11 0%
Friction 0 0% 0 0% 0 0% 5 1% 0 0% 0 0% 0 0% 0 0% 0 0% 5 0%
Wt average 0 0% 0 0% 0 0% 1 0% 0 0% 0 0% 15 5% 0 0% 0 0% 16 1%
Wt variation 1 0% 0 0% 0 0% 3 1% 1 0% 5 2% 12 4% 0 0% 5 2% 27 1%
Not acceptable total 4 1% 0 0% 0 0% 16 5% 5 2% 26 9% 47 16% 7 3% 12 5% 117 4%
Acceptable
Appearance 46 14% 40 14% 41 17% 47 14% 43 14% 43 14% 41 14% 49 17% 38 14% 388 15%
Assay 44 13% 40 14% 41 17% 41 12% 39 13% 32 11% 24 8% 42 14% 34 13% 337 13%
Disintegration 46 14% 40 14% 41 17% 46 14% 43 14% 38 13% 40 14% 49 17% 38 14% 381 14%
Dissolution 45 14% 40 14% 2 1% 5 1% 43 14% 38 13% 39 14% 0 0% 35 13% 247 9%
Friction 0 0% 0 0% 0 0% 40 12% 0 0% 0 0% 0 0% 0 0% 0 0% 40 2%
Identification 46 14% 40 14% 41 17% 47 14% 43 14% 43 14% 41 14% 49 17% 38 14% 388 15%
Irradiance absorption 0 0% 0 0% 0 0% 0 0% 5 2% 0 0% 0 0% 0 0% 0 0% 5 0%
Substantial 0 0% 0 0% 0 0% 2 1% 0 0% 0 0% 0 0% 0 0% 0 0% 2 0%
Water 4 1% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 4 0%
Wt average 46 14% 40 14% 41 17% 46 14% 43 14% 43 14% 26 9% 49 17% 38 14% 372 14%
Wt variation 45 14% 40 14% 41 17% 44 13% 42 14% 38 13% 29 10% 49 17% 33 12% 361 14%
Acceptable total 322 99% 280 100% 248 100% 318 95% 301 98% 275 91% 240 84% 287 97% 254 95% 2525 96%
Grand total 326 100% 280 100% 248 100% 334 100% 306 100% 301 100% 287 100% 294 100% 266 100% 2642 100%
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9Table 7 Sample analysis for drugs by acceptability from urban districts
Amoxicillin Ampicillin Bromhexin Co-trimoxazole Doxycycline Ibuprofen Metronidazole Nystatin Paracetamol Total
#%#%#% # % # %#% # % #%# % # %
Not Acceptable
Assay 9 1% 0 0% 0 0% 0 0% 8 1% 8 1% 6 1% 23 4% 1 0% 55 1%
Disintegration 0 0% 0 0% 0 0% 2 0% 0 0% 36 5% 0 0% 0 0% 6 1% 44 1%
Dissolution 0 0% 0 0% 0 0% 1 0% 1 0% 8 1% 5 1% 0 0% 5 1% 20 0%
Friction 0 0% 0 0% 0 0% 0 0% 0 0% 1 0% 0 0% 0 0% 0 0% 1 0%
Wt Average 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 3 0% 0 0% 0 0% 3 0%
Wt Variation 2 0% 0 0% 0 0% 0 0% 7 1% 2 0% 3 0% 0 0% 1 0% 15 0%
Not Acceptable Total 11 2% 0 0% 0 0% 3 0% 16 3% 55 8% 17 2% 23 4% 13 3% 138 2%
Acceptable Appearance 101 14% 94 14% 106 14% 95 13% 83 14% 95 13% 109 14% 100 17% 65 14% 848 14%
Assay 92 13% 94 14% 106 14% 95 13% 75 13% 87 12% 103 13% 78 13% 64 14% 793 13%
Disintegration 101 14% 94 14% 106 14% 91 12% 83 14% 59 8% 109 14% 100 17% 59 13% 802 13%
Dissolution 101 14% 94 14% 2 0% 93 12% 82 14% 86 12% 101 13% 2 0% 58 13% 619 10%
Friction 1 0% 0 0% 104 14% 94 12% 1 0% 62 9% 3 0% 1 0% 0 0% 266 4%
Identification 101 14% 94 14% 106 14% 95 13% 83 14% 95 13% 109 14% 100 17% 65 14% 848 14%
Wt Average 101 14% 94 14% 106 14% 95 13% 83 14% 95 13% 106 14% 100 17% 65 14% 845 14%
Wt Variation 99 14% 94 14% 106 14% 95 13% 76 13% 93 13% 106 14% 100 17% 64 14% 833 14%
Total Acceptable 697 98% 658 100% 742 100% 753 100% 566 97% 672 92% 746 98% 581 96% 440 97% 5854 98%
Grand Total 708 100% 658 100% 742 100% 756 100% 582 100% 727 100% 763 100% 603 100% 453 100% 5992 100%
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9excluding drug samples from the unlicensed market, where
the prevalence of substandard drugs has found to be sig-
nificantly higher (Almuzaini et al. 2013). Another potential
issue is that the biochemical analysis was performed at 3
different drug testing laboratories in Mongolia. Although
they all used the same Pharmacoepeia standards, the possi-
bility of variability in testing between facilities exists. In
order to confirm the accuracy of the results, we had
planned to send 10% of the samples to an outside lab for
verification. Because of budgetary constraints, only 4 sub-
standard samples (2.2%) were actually sent for testing at an
outside reference laboratory (National Institute of Drug
Quality Control of Vietnam, Hanoi, Vietnam). These 4
samples were all verified as correctly classified, but it is not
a large enough number and did not include any acceptable
samples, therefore we cannot claim to validate our findings
by outside reference laboratory testing.
Another important limitation of our study is that it does
not provide any details about the degree of variation from
the threshold requirements of the Pharmacopeia quality
standards. Our study also does not provide any informa-
tion about the presence of harmful ingredients. Because of
this, our ability to make any inferences about the potential
clinical, safety, or economic impact of the substandard
drugs in Mongolia is limited, but it does support the need
for increased pharmacovigilance and review of drug regu-
latory policies. Further details of the biochemical analysis
of the substandard samples, particularly the degree and
direction of the deviation of the samples failing the assay,
could provide additional valuable insight into the public
health impact of poor drug quality.
Conclusions
Our findings indicate that the presence of substandard
drugs raise a genuine concern in both urban and rural
areas of Mongolia. In addition, we found that unregis-
tered drugs are common in both areas, with a significant
association between substandard and unregistered drugs
in the rural provinces. This highlights an important op-
portunity to improve the quality of the drug supply in
Mongolia by reviewing and enforcing drug registration
and inspection polices. Improving drug storage condi-
tions and importation monitoring at borders are other
interventions that can potentially improve drug supply
quality, especially in rural provinces. Other areas for fur-
ther investigation to better understand the quality of the
drug supply in Mongolia would be to determine the de-
gree of variation in the assay results for substandard
drug samples, sampling the unlicensed market, and in-
vestigating the drug supply chain, especially in the prov-
inces. Another important area for further study of the
public health impact of substandard drugs is evaluating
the patterns of antibiotic resistance and health outcomes
for people living in areas with a high prevalence of sub-
standard drugs.
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